Oxford BioMedica has announced today that a Phase II trial of TroVax in patients with prostate cancer that is unresponsive to hormone therapy is open for recruitment. This is the first clinical trial of TroVax in this cancer type.
The trial is being conducted at the Methodist Hospital in Houston, Texas. The trial is designed to enroll 24 men with hormone-refractory prostate cancer who have previously received chemotherapy or have refused chemotherapy and have progressive disease. The trial is open-label and will have two arms (12 patients each) to assess the activity of TroVax alone versus TroVax alongside an approved treatment for prostate cancer, granulocyte macrophage-colony stimulating factor.